

# Overview and Contents

**Stella Grosser**

Director, Division of Biometrics VIII,  
Office of Biostatistics  
CDER | US FDA

WEBINAR: A Deep Dive: FDA Draft Guidance on Statistical Approaches to  
Establishing Bioequivalence – March 14, 2023

# Overview

- Compare Test and Reference drug products
- Bioequivalence (BE) assessments rely on
  - criterion
  - confidence interval for criterion
  - predetermined limit for concluding BE

# Overview

- Describe ways to statistically compare Test and Reference drug products
- Encourage discussion with FDA as methods and technology evolve
- Includes most topics from 2001, plus additional innovations

# Table of Contents

- I. Introduction
- II. General Considerations
- III. Specific Situations
- IV. (corrected) Appendices

# Table of Contents

## II. General Considerations

A. Study design

B. Data preparation

C. Statistical models

# Study design

## Experimental Design

- non-replicated, replicated,
- adaptive design
- sparse sampling

## Sample Size determination

# Data Preparation

Log-transformation and other data transformation

Missing data and intercurrent events

Outliers

# General Considerations

## Statistical models

Test hypotheses (TOST)

→ confidence intervals

→ mixed effects / two-stage linear models



## Specific Situations

- In-vitro – population BE; In Vitro Release Test, In Vitro Permeation Test; abuse-deterrence formulations; dissolution similarity, profile comparisons
- Pharmacokinetic (PK) – Narrow Therapeutic Index, Highly Variable Drug products; multiple groups;

## Specific Situations

- Pharmacodynamic (PD) – dose scale
- Comparative clinical endpoint
- Adhesion, irritation - transdermal systems

# But wait, there's more....

<b>I.</b>	<b>INTRODUCTION.....</b>	<b>1</b>
	<b>A. Overview.....</b>	<b>1</b>
	<b>B. Statistical Guidance Background.....</b>	<b>2</b>
<b>II.</b>	<b>GENERAL CONSIDERATIONS .....</b>	<b>3</b>
	<b>A. Study Design .....</b>	<b>3</b>
	<b>B. Data Preparation .....</b>	<b>8</b>
	<b>C. Statistical Models.....</b>	<b>11</b>
<b>III.</b>	<b>SPECIFIC SITUATIONS .....</b>	<b>14</b>
	<b>A. In Vitro Bioequivalence and Population Bioequivalence.....</b>	<b>14</b>
	<b>B. Statistical Methods for Narrow Therapeutic Index and         Highly Variable Drug Products .....</b>	<b>19</b>
	<b>C. Comparative Clinical Endpoint Bioequivalence Studies .....</b>	<b>21</b>
	<b>D. Studies in Multiple Groups.....</b>	<b>22</b>
	<b>E. Bioequivalence Statistics for Adhesion and Irritation Studies .....</b>	<b>23</b>
	<b>F. Dose Scale for Bioequivalence Assessment .....</b>	<b>24</b>
	<b>G. Bioequivalence Studies Using Multiple References.....</b>	<b>24</b>
<b>V.</b>	<b>APPENDICES .....</b>	<b>25</b>
	<b>A. Choice of Specific Replicated Crossover Designs .....</b>	<b>25</b>
	<b>B. Rationale for Logarithmic Transformation of Pharmacokinetic Data.....</b>	<b>27</b>
	<b>C. SAS Program Statements for Average Bioequivalence Analysis of         Replicated Crossover Studies.....</b>	<b>28</b>